
This study evaluated the tolerability, safety and pharmacodynamics of different dose‐escalation schemes of the oral small‐molecule glucagon‐like peptide‐1 receptor (GLP‐1R) agonist danuglipron. Danuglipron resulted in statistically significant reductions in HbA1c, FPG and body weight over 12 weeks in the setting of higher discontinuation rates and incidence of gastrointestinal adverse events with higher target doses.
Like
Save
Share